Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD

R. L. Goetgebuer, G. M. C. Masclee, A. A. van der Eijk, C. J. van der Woude, R. A. de Man, A. C. de Vries

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.
Original languageEnglish
Article number101948
JournalClinics and research in hepatology and gastroenterology
Volume46
Issue number7
DOIs
Publication statusPublished - 1 Aug 2022

Keywords

  • Crohn's disease
  • Hepatitis E
  • IBD
  • Vedolizumab

Cite this